Sydney, June 15, 2006 AEST (ABN Newswire) - With reference to the clinical trial currently underway for HeartWare's (ASX: HTW) HVAD left ventricular assist device, Mr McConchie commented:
"The first two patients to have been implanted with the HVAD continue to recover extremely well. Both are now at home, having been released from the Vienna General Hospital where the procedures were conducted.
We now have some 140 days of cumulative clinical implant experience with the device. We have seen no evidence whatsoever of pump related haemolysis or thrombosis and are extremely encouraged by the performance of the device in these first two cases. We look forward to commencing our Australian implant program at the Royal Perth Hospital in coming weeks."
Mr McConchie's presentation included news footage recently screened on Austrian National Television. The video includes brief interviews with the first patient to be implanted with the HVAD and with Dr Georg Wieselthaler, who conducted the procedure.
The news broadcast can be accessed via the HeartWare website at
http://www.heartware.com.au/IRM/content/investor_media.html#
and the presentation can be viewed on Heartware's website:
http://htw.irmau.com/irm/Company/ShowPage.aspx?CPID=1013
Contact
Howard Leibman
Director Corporate Development
HeartWare Limited
TEL: +61 2 9552 4499 / 0404 054 857
| ||
|
